Le Lézard
Classified in: Health, Business
Subjects: VEN, CXP

Comet Bio Completes Equity Financing and Opens U.S. Headquarters in Chicagoland Area


SCHAUMBURG, Ill., July 16, 2019 /PRNewswire/ -- Comet Bio, a manufacturer of healthy and sustainable ingredients, has closed a round of financing with its current investors. The equity funding allows the company to commercialize its flagship products, Arabinoxylan Plant Fiber Extract and Sweeterratm syrups, both of which are made from crop leaves and stalks leftover after a farm's harvest. Existing investors Sofinnova Partners and PM Equity Partner participated in the financing.

"Our products are in high demand because they address consumers' interest in gut health and sugar reduction," said Comet Bio CEO Rich Troyer. "We are pleased to have the ongoing support and confidence of our investors to successfully bring these products to market."

Comet Bio will use the funds to deepen their partnerships to serve food and beverage customers, launch supplement and health food products, complete additional clinical trials to further establish the healthy features of the company's products, and expand its supply chain to meet increasing customer demands. The company has also established their U.S. headquarters in Chicago, IL. Their offices, located at 1501 Perimeter Drive in Schaumburg, will house the company's administrative and commercial functions. Comet Bio chose Chicago for its U.S. headquarters because of the significant number of food and nutrition companies located throughout the region. 

"Consumers are demanding products that are healthy and good for the environment without compromising on taste. A big obstacle for food and beverage companies has been swapping ingredients without sacrificing taste and performance. Comet's innovative ingredients finally provide food and beverage companies a no compromise solution to meet consumer needs," said Jo?ko Bobanovi? of Sofinnova Partners. "We have been impressed by Comet's ability to identify new applications in high demand and look forward to supporting the Comet management team as they commercialize these exciting new products."

"Comet Bio is now well positioned to introduce its healthy ingredients in an appealing range of applications," said Marco Brunazzo of PM Equity Partner. "Comet's products are ideal for supplements and nutritional products, as well as confectionery, fruit preparations and beverages."

Comet Bio produces healthy ingredients from crop leftovers for use in supplements, foods and beverages. The company's Arabinoxylan Plant Fiber Extract is a prebiotic dietary fiber that supports gut health, and a healthy metabolism, while its Sweeterratm syrups are functionally equivalent to traditional sweeteners, and are more sustainable, lower in calories and sugar, and higher in fiber. By upcycling crop leftovers, the company helps farmers utilize their whole harvest, which results in products that are better for the planet. According to an independent well-to-wheel Lifecycle Carbon Emissions Assessment (LCEA), Comet's ingredients reduce greenhouse gases by over 60% compared to traditional sweeteners. In addition, independent tests confirm that Comet's products perform the same as traditional ingredients in many product applications including confectionery, fruit preparations and baking.

About Comet Bio
Comet Bio is a manufacturer of award-winning healthy and sustainable ingredients based in London, Ontario and Schaumburg, Illinois. The company upcycles crop leftovers into healthy and sustainable ingredients for use in supplements, foods, and beverages. The company's two flagship products are Sweeterratm syrup blends and Arabinoxylan dietary fiber that are natural and healthy without compromising on taste or performance. Their ingredients are better for the planet because they reduce greenhouse gases and help farmers take advantage of their whole harvest. For more information, visit http://comet-bio.com/ and follow us on Twitter at @cometbio.

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor from very early stage opportunities to late stage/public companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over ?2.0 billion under management.  For more information, please visit: www.sofinnovapartners.com

About PM Equity Partner
PM Equity Partner invest in entrepreneurs and growth companies that share their vision of profitable sustainability and sustainable profitability. As a long-term investment partner their support includes scientific substantiation, business development and marketing excellence PM Equity Partner is the corporate venture capital and private equity investment arm of Philip Morris International.

 

SOURCE Comet Bio


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: